Abstract OT2-3-07: A randomized, phase 2 study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with temozolomide (TMZ) or in combination with carboplatin (C) and paclitaxel (P) versus placebo plus C/P in subjects with BRCA1 or BRACA2 mutation and metastatic breast cancer
Isakoff, SJ, Pulhalla, S, Shepherd, SP, Falotico, N, Kaufman, B, Friedlander, M, Robson, M, Domchek, S, Garber, J, McKeegan, E, Chyla, B, Qian, J, Giranda, VL
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Published in Cancer research (Chicago, Ill.) (15.12.2012)
Get full text
Journal Article